Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| ISRG |
$476.32 |
-0.5% |
-8.8% |
-19.7% |
-13.0% |
-21.7% |
8↓ |
🟢 Extreme Oversold |
✅ Buy (reduced) |
Price vs Last Deep Dive (02/16)
| Metric |
02/16 |
02/22 |
Change |
| Price |
$476.32 |
$476.32 |
$0.00 (flat) |
| RSI |
8.8 |
8.8 |
0.0 (unchanged — alarming) |
| SMA20 |
$527.40 |
$527.40 |
Unchanged |
| vs SMA |
-9.7% |
-9.7% |
No improvement |
Update from 02/16: Price exactly flat at $476.32 over the 6-day period (02/16 to 02/22) but -8.8% in the most recent 7 days, indicating choppiness around this level. RSI remains stuck at 8.8 — the most sustained extreme-oversold reading we have tracked. This is unusual: typically RSI this low bounces within days. Possible explanations: (1) consistent institutional selling, (2) options hedging, (3) insider selling ($282.6M) providing steady supply. The da Vinci monopoly thesis is unquestionably intact. The concern is timing — RSI can stay extreme for extended periods when supply is persistent.
Company Overview
One-Liner
Intuitive Surgical manufactures and sells the da Vinci robotic surgical system, with a near-monopoly in soft-tissue robotic surgery globally.
Business Model
| Question |
Answer |
| What they sell |
da Vinci surgical systems (hardware), instruments/accessories (per-procedure), service contracts |
| Who pays |
Hospitals, surgical centers globally |
| Revenue model |
System placements (upfront or lease), instrument/accessory consumables (per procedure), annual service contracts |
| How sticky |
Extremely high — hospitals train entire surgical staff, $2M+ installation investment, 10+ year system life |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| Instruments & Accessories |
~60% |
+18% YoY |
Highest-margin, recurring consumable revenue |
| Systems |
~25% |
+12% YoY |
New da Vinci 5 placements |
| Services |
~15% |
+10% YoY |
Annual maintenance contracts |
Competitive Analysis
Competitive Moat
| Moat Type |
Present? |
Evidence |
| Switching costs |
🟢 |
Surgeon training 12-18 months, hospital capital commitment |
| Intangible assets |
🟢 |
10,000+ patents, FDA approvals, 30+ years surgical data |
| Network effects |
🟢 |
More procedures = more outcome data = hospital confidence = more placements |
| Cost advantages |
🟡 |
Premium pricing but justified by outcomes |
| Efficient scale |
🟢 |
10,000+ installed systems globally, impossible to replicate quickly |
Moat Width: Wide
Moat Trend: Widening — da Vinci 5 (new generation) driving upgrade cycle
Competition
- Medtronic Hugo: Behind in FDA approvals, limited procedure indications
- J&J Ottava: In development, not yet commercial
- CMR Surgical (Versius): UK/EU only, lower margin
ISRG has 5-7 year runway before serious competition emerges.
Bull Case
Why This Could Work
- da Vinci monopoly — 10,000+ installed systems globally. No serious commercial competitor for 5+ years.
- Recurring consumable flywheel — Each installed system generates $500K-$1M+ annually in instruments.
- da Vinci 5 upgrade cycle — New generation driving hospital replacement purchases.
- Procedure growth — Robotic procedures growing 15%+ annually globally.
- RSI 8.8 = historical extreme — No quality stock has stayed at RSI < 10 for more than 4-6 weeks without a material bounce.
Upside Scenario
| If This Happens |
Stock Could |
| da Vinci 5 adoption accelerates |
$620 (+30%) |
| RSI normalizes to 50 |
$575 (+21%) |
Bear Case
What Could Go Wrong
- Insider selling continues — $282.6M net selling. If this represents loss of confidence, price pressure continues.
- Procedure volume miss — Hospital capex constraints slow system placements.
- da Vinci 5 adoption slower than expected — Upgrade cycle takes 3-5 years to complete.
- Regulatory issues — New FDA scrutiny on robotic surgery outcomes.
Thesis Killers
- Procedure growth rate drops below 8% for 2 consecutive quarters
- Major hospital system (Kaiser, Mayo) cancels orders for competitor
- Medtronic Hugo achieves FDA approval across major soft-tissue indications
Entry Strategy
Technical Levels
| Level |
Price |
Notes |
| Support 1 |
$455 |
Recent intraday lows |
| Support 2 |
$405 |
Stop-loss; below estimated 52wk low |
| Resistance 1 |
$527.40 |
SMA20 |
| Resistance 2 |
$575 |
3-month prior |
| 52-week high |
$608.48 |
Oct 2025 |
| 52-week low |
~$415 |
(estimated) |
Entry Approach
| Strategy |
Details |
| Entry zone |
$455 - $490 (current levels) |
| Position |
1-2% (reduced from normal due to persistent RSI anomaly) |
| Add |
If RSI breaks above 15 with stabilizing price |
| Stop |
$405 (-15%) |
Research Log
| Date |
Update |
| 2026-02-16 |
Created deep dive. RSI 8.8 extreme. $476.32. Insider selling -$282.6M adds caution. Action: Buy (with caution). |
| 2026-02-22 |
Price refresh. $476.32 (flat). RSI 8.8 unchanged — 6+ days at extreme. -8.8% this week. -19.7% 30D. Continued RSI 8.8 without bounce is unusual — maintain reduced position size thesis. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 8.8 unchanged for 6+ days |
Sustained selling pressure — not a one-day capitulation spike |
| Insider selling $282.6M net |
Management/insiders reducing exposure despite "cheap" RSI |
| da Vinci 5 upgrade cycle underway |
Long-term fundamentals remain excellent |
| -21.7% from 52wkHi |
Still well off highs despite 6 weeks of selling |
Open Questions
- Are the insider sales on a pre-planned 10b5-1 schedule or discretionary?
- What is the da Vinci 5 system placement pace vs expectations?
- Is RSI staying at 8.8 due to index rebalancing / ETF selling?
- When is the next earnings report for any procedure volume update?
Mistakes (Don't Repeat)
| Mistake |
Lesson |
| RSI 8.8 doesn't guarantee immediate bounce |
Insider selling can suppress price even at extreme technical levels |
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.